STOCK TITAN

Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has announced upcoming presentations by its executive management team at two major healthcare conferences in June 2025. At the Jefferies Global Healthcare Conference on June 4, EVP U.S. Commercial Chris Fox and EVP Global R&D and Chief Medical Officer Dr. Eric Hughes will present at 9:20 am ET. At the Goldman Sachs 46th Annual Global Healthcare Conference on June 10, President & CEO Richard Francis will present at 8:00 am ET. Live webcasts will be available on Teva's Investor Relations website, with archived versions accessible within 24 hours after each presentation.

Teva Pharmaceutical Industries Ltd. (NYSE e TASE: TEVA) ha annunciato le prossime presentazioni del suo team di gestione esecutiva in due importanti conferenze sanitarie a giugno 2025. Alla Jefferies Global Healthcare Conference del 4 giugno, l'EVP U.S. Commercial Chris Fox e l'EVP Global R&D e Chief Medical Officer Dr. Eric Hughes presenteranno alle 9:20 ET. Alla Goldman Sachs 46th Annual Global Healthcare Conference del 10 giugno, il Presidente e CEO Richard Francis presenterà alle 8:00 ET. Le dirette streaming saranno disponibili sul sito web delle Relazioni con gli Investitori di Teva, con versioni archiviate accessibili entro 24 ore da ogni presentazione.

Teva Pharmaceutical Industries Ltd. (NYSE y TASE: TEVA) ha anunciado próximas presentaciones de su equipo ejecutivo en dos importantes conferencias de salud en junio de 2025. En la Jefferies Global Healthcare Conference el 4 de junio, el EVP de Comercialización en EE.UU. Chris Fox y el EVP de I+D Global y Director Médico Dr. Eric Hughes presentarán a las 9:20 am ET. En la Goldman Sachs 46th Annual Global Healthcare Conference el 10 de junio, el Presidente y CEO Richard Francis presentará a las 8:00 am ET. Las transmisiones en vivo estarán disponibles en el sitio web de Relaciones con Inversionistas de Teva, con versiones archivadas accesibles dentro de las 24 horas posteriores a cada presentación.

Teva Pharmaceutical Industries Ltd. (NYSE 및 TASE: TEVA)는 2025년 6월 두 개의 주요 헬스케어 컨퍼런스에서 경영진의 발표 일정을 발표했습니다. 6월 4일 Jefferies Global Healthcare Conference에서는 미국 상업 부문 EVP 크리스 폭스와 글로벌 연구개발 및 최고 의료 책임자 Dr. 에릭 휴즈가 동부시간 기준 오전 9시 20분에 발표할 예정입니다. 6월 10일 Goldman Sachs 46th Annual Global Healthcare Conference에서는 사장 겸 CEO 리처드 프랜시스가 동부시간 기준 오전 8시에 발표합니다. 라이브 웹캐스트는 Teva 투자자 관계 웹사이트에서 제공되며, 각 발표 후 24시간 이내에 아카이브 버전도 이용할 수 있습니다.

Teva Pharmaceutical Industries Ltd. (NYSE et TASE : TEVA) a annoncé les prochaines présentations de son équipe de direction lors de deux grandes conférences sur la santé en juin 2025. Lors de la Jefferies Global Healthcare Conference le 4 juin, le EVP U.S. Commercial Chris Fox et le EVP Global R&D ainsi que Chief Medical Officer Dr Eric Hughes présenteront à 9h20 ET. Lors de la Goldman Sachs 46th Annual Global Healthcare Conference le 10 juin, le Président & CEO Richard Francis prendra la parole à 8h00 ET. Des webcasts en direct seront disponibles sur le site des Relations Investisseurs de Teva, avec des versions archivées accessibles dans les 24 heures suivant chaque présentation.

Teva Pharmaceutical Industries Ltd. (NYSE und TASE: TEVA) hat bevorstehende Präsentationen seines Executive-Management-Teams auf zwei großen Gesundheitskonferenzen im Juni 2025 angekündigt. Auf der Jefferies Global Healthcare Conference am 4. Juni werden EVP U.S. Commercial Chris Fox und EVP Global F&E sowie Chief Medical Officer Dr. Eric Hughes um 9:20 Uhr ET präsentieren. Auf der Goldman Sachs 46th Annual Global Healthcare Conference am 10. Juni wird Präsident und CEO Richard Francis um 8:00 Uhr ET sprechen. Live-Webcasts sind auf der Investor-Relations-Website von Teva verfügbar, mit archivierten Versionen, die innerhalb von 24 Stunden nach jeder Präsentation abrufbar sind.

Positive
  • None.
Negative
  • None.

TEL AVIV, Israel, May 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that members of its executive management team will present at two upcoming investor conferences in June as follows:

  • Jefferies Global Healthcare Conference
    Chris Fox, EVP U.S. Commercial and Dr. Eric Hughes, EVP Global R&D and Chief Medical Officer
    Wednesday, June 4, 2025, at 9:20 am ET
  • Goldman Sachs 46th Annual Global Healthcare Conference
    Richard Francis, President & CEO
    Tuesday, June 10, 2025, at 8:00 am ET

To access a live webcast of the presentation, visit Teva’s Investor Relations website at https://ir.tevapharm.com/Events-and-Presentations.

An archived version of the webcast will be available within 24 hours after the end of the live discussion.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a different kind of global pharmaceutical leader, one that operates across the full spectrum of innovation to reliably deliver medicines to patients worldwide. For over 120 years, Teva’s commitment to bettering health has never wavered. Today, the company’s global network of capabilities enables its 37,000 employees across 57 markets to advance health by developing medicines for the future while championing the production of generics and biologics. If patients have a need, we’re already working to address it. To learn more about how Teva is all in for better health, visit www.tevapharm.com.

Cautionary Note Regarding Forward-Looking Statements

This document and the presentation at the conference may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace including our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, and to sustain and focus our portfolio of generics medicines; our substantial indebtedness; our business and operations in general including the impact of global economic conditions and other macroeconomic developments and the governmental and societal responses thereto; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the sections captioned "Risk Factors.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.


FAQ

When will Teva (TEVA) present at the Jefferies Global Healthcare Conference 2025?

Teva will present at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 9:20 am ET, featuring Chris Fox and Dr. Eric Hughes.

Who will represent Teva at the Goldman Sachs Healthcare Conference 2025?

Richard Francis, President & CEO of Teva, will present at the Goldman Sachs Global Healthcare Conference on June 10, 2025.

How can investors access Teva's presentations at the June 2025 healthcare conferences?

Investors can access live webcasts of the presentations through Teva's Investor Relations website at https://ir.tevapharm.com/Events-and-Presentations.

When will the archived versions of Teva's conference presentations be available?

Archived versions of the webcasts will be available within 24 hours after the end of each live discussion.
Teva Pharm

NYSE:TEVA

TEVA Rankings

TEVA Latest News

TEVA Stock Data

19.24B
1.15B
0%
60.32%
2.43%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
Israel
TEL AVIV